Viatris

Viatris

Yahoo Finance • 5 days ago

ISCV vs. IWN: Which Small-Cap Value ETF Is the Better Buy?

While both funds target smaller U.S. companies that appear undervalued relative to the broader market, the iShares Morningstar Small-Cap Value ETF (NYSEMKT:ISCV) provides that exposure to the small-cap value space at a lower cost than the... Full story

Yahoo Finance • 10 days ago

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds A company that generates cash isn't automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luckily for y... Full story

Yahoo Finance • 11 days ago

Viatris Recognized as One of the 2026 Best Workplaces™ in Canada

ETOBICOKE, ON, June 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) has been recognized as one of the 2026 Best Workplaces™ in Canada by Great Place to Work®. This recognition highlights Viatris' commitment to fostering a culture wher... Full story

Yahoo Finance • 15 days ago

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Investors deciding between Lexicon Pharmaceuticals(NASDAQ:LXRX) and Pfizer(NYSE:PFE) face a choice between an emerging high-growth biotech player and an established global pharmaceutical titan with massive scale. These two companies opera... Full story

Yahoo Finance • 30 days ago

Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Amneal (NASDAQ:AMRX) and the best and worst performers in the generic pharmaceutic... Full story

Yahoo Finance • last month

Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsight

The acute myocardial infarction market is experiencing steady growth driven by rising global cardiovascular disease prevalence and expanding geriatric populations. Advances in diagnostic technologies and rapid-acting therapies are accelera... Full story

Yahoo Finance • last month

TrumpRx set to expand into generic medicines with Mark Cuban

Heather Diehl/Getty Images News * Mark Cuban, the billionaire co-founder of the Cost Plus Drugs online pharmacy, is expected to join President Trump Monday afternoon as part of an announcement that the TrumpRx website will now carry gen... Full story

Yahoo Finance • 2 months ago

Most healthcare companies report higher Y/Y EPS in strong earnings week

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare companies delivered strong earnings this week, with 18 out of 20 companies beating EPS estimates and 15 t... Full story

Yahoo Finance • 2 months ago

Chris Davis Significantly Reduces Stake in Applied Materials Inc, Impacting Portfolio by -3.47%

This article first appeared on GuruFocus. Insight into Chris Davis (Trades, Portfolio)'s Strategic Moves in Q1 2026 Warning! GuruFocus has detected 4 Warning Sign with AIG. Is COF fairly valued? Test your thesis with our free DCF calcula... Full story

Yahoo Finance • 2 months ago

Cardiogenic Shock Analysis Report 2026: Market to Reach $5.2 Billion by 2030, Driven by Minimally Invasive Techniques, AI Adoption. and Aging Populations

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Cardiogenic Shock Market: 2026 Edition" has been added to ResearchAndMarkets.com's offering. The global cardiogenic shock market value in 2024 stood at US$3.57 billion, and is projected to... Full story

Yahoo Finance • 2 months ago

Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard

[Magnifying Glass On Top Of Bar Chart] DNY59 Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over-year EPS growth. All 22 companies recorded year-over-year revenue i... Full story

Yahoo Finance • 2 months ago

Chlorpheniramine Maleate - Global Market Insights, Competitive Landscape & Industry Forecast to 2033 Featuring Viatris, Alkem Labs, Merck & Co., Johnson & Johnson, Capellon Pharma and More

Company Logo The chlorpheniramine maleate market is poised for growth due to rising allergic conditions, OTC antihistamine awareness, and pharmaceutical innovation Dublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Chlorpheniramine Maleate Ma... Full story

Yahoo Finance • 2 months ago

QSM Asset Management Loads Up 611,000 Mobileye Shares

Key Points QSM Asset Management Ltd bought 611,003 shares of Mobileye, with an estimated trade value of $5.54 million based on quarterly average pricing. The quarter-end value of the new Mobileye stake was $4.13 million. This trade repres... Full story

Yahoo Finance • 2 months ago

Quant check on David Einhorn's Greenlight Capital holdings post Q1

[Close up image of wooden cubes with alphabet Q1 on office desk.] mohd izzuan David Einhorn's Greenlight Capital funds gave a return of 6.5% in Q1 vs. a broader market drop of 4.4% in the S&P 500 index. The significant winners in the quar... Full story

Yahoo Finance • 3 months ago

Australia Drug Delivery Devices Market Trends by Type of Product, Application Area and End-user - Forecast to 2035

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Australia Drug Delivery Devices Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Application Area and End-user" has been added to ResearchAndMarke... Full story

Yahoo Finance • 3 months ago

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story

Yahoo Finance • 3 months ago

Viatris Outlines Long-term Financial Targets

(RTTNews) - Viatris (VTRS) said, for combined long-term Targets through 2030, the company expects to deliver 5% to 6% total revenues CAGR, 7% to 8% adjusted EBITDA CAGR, 9% to 10% adjusted EPS CAGR and more than $3 billion in annual free c... Full story

Yahoo Finance • 3 months ago

1 Cash-Producing Stock to Target This Week and 2 That Underwhelm

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. Not all companies are created equal, a... Full story

Yahoo Finance • 3 months ago

ISCV vs. VBR: Which Small Cap Value Approach is Right for Investors?

The Vanguard Small-Cap Value ETF (NYSEMKT:VBR) and iShares Morningstar Small-Cap Value ETF(NYSEMKT:ISCV) both target U.S. small-cap value stocks, but ISCV offers a marginally higher yield, heavier exposure to financial services, and much s... Full story

Yahoo Finance • 3 months ago

What Are Analysts Saying About Viatris Inc (VTRS) Stock?

Viatris Inc. (NASDAQ:VTRS) is one of the 13 extreme value stocks to buy now. Viatris Inc. (NASDAQ:VTRS) is covered by 12 analysts on Wall Street with a medium price target of $16, suggesting 12.36% upside from current levels. On February 2... Full story